Methotrexate should not be prescribed to every systemic glucocorticoid-dependent asthmatic. In fact, while methotrexate may be advantageous in selected patients, every attempt to control asthma with regular anti-asthma agents should be made. Most studies on the effects of methotrexate in the treatment of systemic glucocorticoid-dependent asthmatics include small numbers of patients and are all of relatively short duration. Thus, large long-term multicentre trials are urgently needed. In these studies, a uniform accepted definition of systemic glucocorticoid-dependent asthmatics should be used. For the time being, we reinforce the recommendation of the NHLBI/ WHO panel that methotrexate and other systemic glucocorticoid sparing drugs should be considered experimental medications, and used only in selected patients under the supervision of an asthma specialist with previous experimental experience.

Methotrexate in the treatment of systemic glucocorticoid-dependent severe persistent asthma: a word of caution / Fabbri, Leonardo; Caramori, G; Cosma, P; Ciaccia, A.. - In: MONALDI ARCHIVES FOR CHEST DISEASE. - ISSN 1122-0643. - STAMPA. - 51:(1996), pp. 130-137.

Methotrexate in the treatment of systemic glucocorticoid-dependent severe persistent asthma: a word of caution.

FABBRI, Leonardo;
1996

Abstract

Methotrexate should not be prescribed to every systemic glucocorticoid-dependent asthmatic. In fact, while methotrexate may be advantageous in selected patients, every attempt to control asthma with regular anti-asthma agents should be made. Most studies on the effects of methotrexate in the treatment of systemic glucocorticoid-dependent asthmatics include small numbers of patients and are all of relatively short duration. Thus, large long-term multicentre trials are urgently needed. In these studies, a uniform accepted definition of systemic glucocorticoid-dependent asthmatics should be used. For the time being, we reinforce the recommendation of the NHLBI/ WHO panel that methotrexate and other systemic glucocorticoid sparing drugs should be considered experimental medications, and used only in selected patients under the supervision of an asthma specialist with previous experimental experience.
1996
51
130
137
Methotrexate in the treatment of systemic glucocorticoid-dependent severe persistent asthma: a word of caution / Fabbri, Leonardo; Caramori, G; Cosma, P; Ciaccia, A.. - In: MONALDI ARCHIVES FOR CHEST DISEASE. - ISSN 1122-0643. - STAMPA. - 51:(1996), pp. 130-137.
Fabbri, Leonardo; Caramori, G; Cosma, P; Ciaccia, A.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/806307
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 3
  • ???jsp.display-item.citation.isi??? ND
social impact